Betalin Therapeutics is developing an Engineered Micro Pancreas (EMP) to improve the quality of life for millions of people with diabetes.
Betalin Therapeutics, founded by Prof Ed Mitrani, licensed the novel EMP technology developed at The Hebrew University of Jerusalem, Israel, in an exclusive worldwide agreement in 2015. The Hebrew University continues to partner with Betalin Therapeutics to support the research and development.
Based on promising in-vitro results and preliminary in-vivo results, Betalin Therapeutics has recently submitted a pre-pre-IND (Investigational New Drug) application to the Food and Drug Administration (FDA). Following the FDA’s positive response, Betalin Therapeutics is now preparing the pre-IND meeting on its way towards IND submission.
For more information, see: https://www.linkedin.com/pulse/israeli-startup-wants-cure-diabetes-making-worked-mice-ruti-alon
See Betalin Therapuetics’ site: http://www.betalintherapeutics.com/